To hear about similar clinical trials, please enter your email below
Trial Title:
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
NCT ID:
NCT02174679
Condition:
Carcinoid Cancer
Neuroendocrine Tumors
Medullary Thyroid Cancer
Cancers Expressing Somatostatin Receptors
Conditions: Official terms:
Neuroendocrine Tumors
Study type:
Expanded Access
Overall status:
No longer available
Intervention:
Intervention type:
Drug
Intervention name:
68Ga DOTATATE
Description:
Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
Other name:
68Ga DOTATATE PET/CT Scan
Summary:
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine
tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Detailed description:
This is an expanded access study with a total of 300 participants with NET and suspected SSTR
positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study
participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients
referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then
accepted for scanning if clinically appropriate.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Older than 18 years the time of radiotracer administration
- Provides written informed consent
- Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age
must have a negative pregnancy test at screening/baseline
- Able to remain still for duration of each imaging procedure (about 30 minutes)
Exclusion Criteria:
- Less than 18 years-old at the time of radiotracer administration
- Pregnant or nursing
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious concurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Locations:
Facility:
Name:
UCLA Hospital
Address:
City:
Los Angeles
Zip:
90095
Country:
United States
Lead sponsor:
Agency:
Jonsson Comprehensive Cancer Center
Agency class:
Other
Source:
Jonsson Comprehensive Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on March 01, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT02174679
http://pet.ucla.edu